Global Biologics Market - Forecasts From 2018 to 2023

November 2018 | 106 pages | ID: G2BFF8591CAEN
Knowledge Sourcing Intelligence LLP

Abstracts

The global biologics market is expected to reach US$310.776 billion by 2023 from US$236.121 billion in 2017 growing at a CAGR of 4.69%. Biologics or biologic drug is a produced from living organisms or contain components of living organisms. They can be derived from human, animal, or microorganisms by using biotechnological techniques. Biologics consists of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Most biologics are complex mixtures that cannot be easily identified or characterized and tend to be heat sensitive and susceptible to microbial contamination. The biologics market is expected to show a significant growth during the given forecast period owing to the growing capital investments from key market players. Recently in Oct 2018, Merck announced the building of second manufacturing plant for vaccines and biologics in Ireland due to growing demand for the company’s medicines and vaccines. Growing adoption of the innovative therapies for the treatment of various disorders will also augment the growth of the market during the forecast period. However, stringent regulatory requirements for the market approval of biologics might restrain the market for biologics during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Biologics market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global biologics market.

Major industry players profiled as part of the report are F. Hoffmann-La Roche Ltd, Samsung Biologics and Shire plc among others.

Segmentation

By Type
Monoclonal Antibodies
Vaccines
Recombinant Proteins
Gene Therapy
Others
By Application
Oncology
Neurology
Orphan Indications
Infectious Diseases
Others
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others

Contents

1. INTRODUCTION

1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. KEY FINDINGS OF THE STUDY

4. MARKET DYNAMICS

4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis

5. GLOBAL BIOLOGICS MARKET FORECAST BY TYPE

5.1. Monoclonal Antibodies
5.2. Vaccines
5.3. Recombinant Proteins
5.4. Gene Therapy
5.5. Others

6. GLOBAL BIOLOGICS MARKET FORECAST BY APPLICATION

6.1. Oncology
6.2. Neurology
6.3. Orphan Indications
6.4. Infectious Diseases
6.5. Others

7. GLOBAL BIOLOGICS MARKET FORECAST BY GEOGRAPHY

7.1. North America
  7.1.1. The U.S
  7.1.2. Canada
  7.1.3. Mexico
  7.1.4. Others
7.2. South America
  7.2.1. Brazil
  7.2.2. Argentina
  7.2.3. Others
7.3. Europe
  7.3.1. U.K.
  7.3.2. France
  7.3.3. Germany
  7.3.4. Italy
  7.3.5. Others
7.4. Middle East and Africa
  7.4.1. Saudi Arabia
  7.4.2. UAE
  7.4.3. Israel
  7.4.4. Others
7.5. Asia Pacific
  7.5.1. China
  7.5.2. India
  7.5.3. Australia
  7.5.4. South Korea
  7.5.5. Others

8. COMPETITIVE INTELLIGENCE

8.1. Market Share Analysis
8.2. Strategies of Key Players
8.3. Recent Investments and Deals

9. COMPANY PROFILES

9.1. F. Hoffmann-La Roche Ltd
  9.1.1. Overview
  9.1.2. Financials
  9.1.3. Product and Services
  9.1.4. Recent Developments
9.2. Amgen Inc
  9.2.1. Overview
  9.2.2. Financials
  9.2.3. Product and Services
  9.2.4. Recent Developments
9.3. AbbVie Inc
  9.3.1. Overview
  9.3.2. Financials
  9.3.3. Product and Services
  9.3.4. Recent Developments
9.4. Novo Nordisk AS
  9.4.1. Overview
  9.4.2. Financials
  9.4.3. Product and Services
  9.4.4. Recent Developments
9.5. Johnson & Johnson
  9.5.1. Overview
  9.5.2. Financials
  9.5.3. Product and Services
  9.5.4. Recent Developments
9.6. Shire PLC
  9.6.1. Overview
  9.6.2. Financials
  9.6.3. Product and Services
  9.6.4. Recent Developments
9.7. Gilead Sciences
  9.7.1. Overview
  9.7.2. Financials
  9.7.3. Product and Services
  9.7.4. Recent Developments
9.8. Alexion Pharmaceuticals
  9.8.1. Overview
  9.8.2. Financials
  9.8.3. Product and Services
  9.8.4. Recent Developments
9.9. Samsung Biologics
  9.9.1. Overview
  9.9.2. Financials
  9.9.3. Product and Services
  9.9.4. Recent Developments
9.10. UCB
  9.10.1. Overview
  9.10.2. Financials
  9.10.3. Product and Services
  9.10.4. Recent Developments